A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures

A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)

This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.

Inclusion Criteria:

• Male/female 4-17 years old having participated in study N162 or in study N163
• suffering from typical absences with 3 Hz spike-wave discharges, with or without tonic-clonic seizures, in CAE or JAE
• expected reasonable benefit (efficacy and tolerability) of levetiracetam long term administration

Exclusion Criteria:

• allergy/intolerance to pyrrolidine derivatives and/or excipients
• use of > 2 concomitant antiepileptic treatment or valproate, ethosuximide or lamotrigine